Compare FBIN & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBIN | PCVX |
|---|---|---|
| Founded | 1988 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.1B |
| IPO Year | 2011 | 2020 |
| Metric | FBIN | PCVX |
|---|---|---|
| Price | $45.43 | $56.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $61.40 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 3.4M | 1.1M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $4,463,200,000.00 | N/A |
| Revenue This Year | $2.75 | N/A |
| Revenue Next Year | $3.64 | N/A |
| P/E Ratio | $18.34 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $44.04 | $28.09 |
| 52 Week High | $64.84 | $76.61 |
| Indicator | FBIN | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 29.11 | 48.91 |
| Support Level | $44.04 | $42.30 |
| Resistance Level | $53.81 | $57.50 |
| Average True Range (ATR) | 2.10 | 2.92 |
| MACD | -1.02 | -0.65 |
| Stochastic Oscillator | 9.57 | 12.44 |
Fortune Brands Innovations is a leading home and security products company that has three reportable segments. The company's $2.6 billion water segment, led by the Moen brand, sells faucets, showers, and other plumbing fixtures; the $1.4 billion outdoors segment primarily sells entry doors under the Therma-Tru brand name and Fiberon-branded patio decking; and the $700 million security segment sells locks and other security devices under the Master Lock, SentrySafe, Yale, and August brand names.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.